Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences
Ryan Allway
September 14th, 2021
News
– Resurgent is recruiting 100 participants to take part in the anonymous online survey –
– The research from the study will help to better inform the design of future research and therapies –
— Study is first of its kind to receive approval from an independent Institutional Review Board (“IRB”) –
MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences, Inc. (“Resurgent”), is actively recruiting 100 participants to take part in an anonymous online survey to research the varying effects of entheogen and psychedelic experiences for therapeutic, religious, or spiritual purposes. The research will help inform Resurgent on future developments including research and wellness applications designed to help promote more positive, long-lasting outcomes from psychedelic-based therapies.
Existing research into the therapeutic use of psychedelics has focused heavily on synthetic substances, such as LSD, Ketamine, and MDMA, performed in controlled clinical settings. The survey being conducted by Resurgent, which has received approval from an independent Institutional Review Board (“IRB”) registered with the Office for Human Research Protections (“OHRP”), will instead focus on the naturalistic use of entheogens and other substances typically used in specific cultural and spiritual contexts for healing.
“Entheogens” refers to traditional substances, more commonly referred to as psychedelics, of fully natural origin and ingested to impact one’s consciousness for therapeutic, religious, or spiritual purposes. This is an innovative, first-of-its-kind survey delving into some key questions surrounding entheogen usage.
“Lab-based research will always be an essential aspect of our research and development process. However, to create more effective psychedelic-based therapies and services, we believe it is equally important to thoroughly explore the tremendous wealth of experience and wisdom that already exists and is active today based on centuries of both spiritual and therapeutic practices,” said Chief Medical Officer Stephen Dahmer, MD. “Learning from and respecting the rich history of psychedelic traditional practices as well as the extensive existing therapeutic use is an important first step to support a path for future therapies in the United States that afford long term safety and efficacy.”
To conduct this research, Resurgent will be performing an observational pilot survey, collecting self-reported, anonymous data from 100 adults who self-report having participated in entheogen therapy centers and retreats during the last five years on topics including their initial intentions, motivations, experiences, demographics, and willingness to participate in future entheogen research.
By collecting information from psychedelic-related ceremonies and retreats across the world, and particularly in South America, Resurgent aims to gain a greater understanding of these experiences and their impact on participants to develop better approaches for psychedelic-focused therapy and counselling.
“As a science-focused company, research remains the first and most important step in the development of new therapeutic approaches and supportive solutions related to psychedelics,” said Chairman and Chief Executive Officer, Kyle Kingsley, M.D. “As we work to further our understanding and acceptance of psychedelic-based therapies as beneficial, an IRB-approved research study will enable us to gather meaningful data to refine and focus our approach to development of products related to psychedelics therapy.”
The research study is being conducted through a partnership with Flor da Jurema, a temple community in Brazil, where visitors can practice traditional forms of plant-based medicines and take part in spiritual experiences around the globe.
To learn more, please visit the study’s page on the National Institute of Health’s Clinical Trials Website.
To participate in this study, visit https://redcap.link/SERPNTS.
About Goodness Growth Holdings, Inc.
Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company’s operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, Inc., and its science and intellectual property incubator, Resurgent Biosciences, Inc. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods® and other retail locations and third-party dispensaries. Its team of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 18 dispensaries across the United States. For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com.
|
Contact Information |
|
|
Investor Inquiries: |
Media Inquiries: |
|
Sam Gibbons |
Albe Zakes |
|
Vice President, Investor Relations |
Vice President, Corporate Communications |
|
(612) 314-8995 |
(267) 221-4800 |
SOURCE Goodness Growth Holdings
Related Links
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Mojave Jane Brands Inc. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including cultivation to scale, branding, packaging, manufacturing & processing, as well as, […]
Weekend Unlimited aggregates and scales small to medium cannabis brands in flower, extracts, and edibles.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
